ArticleScientific reports2026
The association between systemic inflammation markers and breast cancer.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Breast cancer is one of the most common malignant tumors in women worldwide. Inflammation plays an important role in the occurrence and development of breast cancer. This study aimed to evaluate the association between inflammatory markers and breast cancer prevalence and explore their potential biomarker value. Using data from the NHANES, approximately 20,000 participants were analyzed to assess the association between six systemic inflammatory markers and breast cancer prevalence. Statistical methods including multivariable logistic regression, subgroup analysis, and interaction testing were employed. ROC curves were used to evaluate and compare their diagnostic capabilities. This study included 19,734 participants. We observed a significant positive correlation between platelet-to-lymphocyte ratio (PLR) and breast cancer prevalence (OR = 1.35; 95% CI:1.09, 1.67), with PLR demonstrating good predictive performance for breast cancer. Additionally, monocyte-to-lymphocyte ratio (MLR), neutrophil-to-lymphocyte ratio (NLR), systemic immune-inflammation index (SII), systemic inflammation response index(SIRI) and aggregate index of systemic inflammation(AISI) were also found to be positively associated with breast cancer prevalence. Subgroup analysis and interaction tests revealed that the association between PLR and BC did not differ significantly among population groups. ROC curve analysis indicated that PLR (AUC = 0.59; 95%CI: 0.56, 0.63) outperformed other inflammatory markers in predicting BC. Systemic inflammatory markers, especially PLR, are significantly associated with BC prevalence and demonstrate potential as biomarkers for early detectionn. People with elevated inflammation markers should pay close attention to the latent prevalence of BC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.